References
- Frosst P, Blom HJ, Milos R, Sheppard CA, Matthews RG, Boers GJ, Den Heijer M, Kluijtmans LA, Van Den Heuvel LP, Rozen R, et al. A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Gen 1995; 10: 111–3
- Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395–403
- Fujimura H, Kawasaki T, Sakata T. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res 2000; 98: 1–8
- Hak AE, Polderman KH, Westendrop IC, Jakobs C, Hofman A, Witterman JC, Stehouwer CD, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000; 149: 163
- Madsen JS, Kristensen SR, Klitgaard NA, Bladbjerg EM, Abrahamsen B, Stilgren L, Jespersen J, et al. Effect of longterm hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am J Obstet Gynecol 2002; 187: 33–9
- Mijatovic V, van der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clin Chem Lab Med 2001; 39: 764–7
- Chiantera V, Sarti CD, Fornaro F, Farzati A, Franciscis P, Sepe E, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 10: 286–91
- Van Baal WM, Smolders RGV, Van Der Mooren MJ, Teerlink T, Kenemans P. Hormone replacement therapy and plasma homocysteine. Obstet Gynecol 1999; 94: 485–91
- Hak AE, Bak AA, Lindemans J, Planellas J, Coelingh Bennink HJ, Hofman A, Grobbee DE, Witteman JC. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis 2001; 158: 437
- Evio S, Tiitinen A, Turpeinen U, Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 2000; 74: 1081–3
- Bruschi F, Dal Pino D, Fiore V, Parazzini F, Di Pace R, Casena BM, Melotti D, Crosignani PG, et al. Effect of oral or transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial. Maturitas 2004; 48: 33–8
- Bukowska H, Stanosz S, Zochowska E, Millo B, Sieja K, Cheystowski K, et al. Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women?. Metabolism 2005; 54: 72–8
- D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet Gynecol Scand. 2005; 84: 474–7
- Arruda VR, Siqueira LH, Gonçalves MS, Von Zuben PM, Soares MC, Menezes R, Annichino-Bizzacchi JM, Costa FF, et al. Prevalence of mutation C677T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet 1998; 78: 332–5
- Women's Health Initiative. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–33
- Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004; 148: 34